Naltrexone

CODAC Behavioral Healthcare to Present at 2022 AATOD Conference

Retrieved on: 
星期四, 十月 20, 2022
Linda, Rhode Island Department of Health, Time, Brown University School of Public Health, Risk, Government, Associate professor, Methadone, MAT, Public health, Conference, OTP, Prison, Patient, Opioid use disorder, RIDOC, Program, Drug, Ageing, Justice, Center of excellence, Treatment, MD, Doctor of Philosophy, Rhode Island Department of Corrections, Department, American Association, DO, Buprenorphine, Association, Research, Fentanyl, Comprehensive Model of Information Seeking, Success, Wisconsin Department of Justice, Opioid, MA, Death, Naltrexone, Center, SAMHSA, Health insurance, Management, Pharmaceutical industry, Corrections

· Tuesday, November 1, 2022 -- 1:30 PM - 3:00 PM Workshop: Patient Care & Best Practices 1 - Effectively Treating the Aging and Elderly in Opioid Treatment Programs: A Comprehensive Model Primary Presenter(s): Linda Hurley, MA CAGS, President and Chief Executive Officer, CODAC Co-Presenter(s): Andrew C. Stone, MD, Medical Director of CODAC Providence; Catherine DeGood, DO, Chief Medical Director for CODAC

Key Points: 
  • The theme of this national and international Conference is " The Power of Collaboration .
  • CODAC Behavioral Healthcare, a non-profit organization founded in 1971, is Rhode Island's oldest and largest provider of outpatient services for opioid use disorder, other substance use disorders, and concurrent behavioral health challenges.
  • With eight locations across Rhode Island, CODAC has attained Center of Excellence designations for each of its treatment sites.
  • For more information about CODAC, visit: http://www.codacinc.org
    The 2022 American Association for the Treatment of Opioid Dependence, Inc. (AATOD) Conference will be held in Baltimore, Maryland at the Baltimore Hilton Inner Harbor, October 30 - November 3, 2022.

BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

Retrieved on: 
星期四, 十月 13, 2022
National Institute, CBT, Substance abuse, NIDA, Plague, OUD, IND, Volunteering, Drug development, National Institute on Drug Abuse, NIH, Opioid use disorder, Investigational New Drug, Clinical trial, Company, RFA, Orange County, National, Pharmacokinetics, CEO, Research, Nutritionist, Safety, GLOBE, FDA, NCT, AUD, OTCQB, Solution, Cognitive behavioral therapy, Pharmaceutical industry, Drug overdose, Naltrexone

We plan to add additional subjects to complete the FDA-required clinical characterization of BICX104 prior to seeking marketing approval potentially in 2023.

Key Points: 
  • We plan to add additional subjects to complete the FDA-required clinical characterization of BICX104 prior to seeking marketing approval potentially in 2023.
  • The study is led by Dr. Joel M. Neutel M.D., Director of Research at the Orange County Research Center (OCRC), located in Tustin, CA.
  • BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders.
  • The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders.

InvestmentPitch Media Video Discusses LOVE Pharma’s Signing of Non-Binding LOI to Acquire 100% of Naltrexone Therapeutics Inc., a Pharmaceutical Technology Company with Significant IP Related to the Transdermal Delivery of FDA Approved Naltrexone

Retrieved on: 
星期三, 十月 12, 2022
Quality of life, News, FSE, Speech disorder, Risk, Therapy, Nausea, Growth, CDN, Patient, Opioid use disorder, Euphoria, Company, Naltrexone, US, Health minister, CSE, CEO, Awareness, Absorption, Suggestion, Intention, GLOBE, United Kingdom, LOVE, Letter, FDA, Wellness, Love, Pharmaceutical industry

If these links are not enabled, please visit www.InvestmentPitch.com and enter Love Pharma in the search box.

Key Points: 
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter Love Pharma in the search box.
  • Transdermal delivery of Naltrexone is anticipated to regulate dosage, reduce GI related side effects and improve the patient experience overall.
  • Zach Stadnyk, President and CEO, stated: "Love Pharma is very excited to add the Naltrexone Therapeutics transdermal patch IP to our addiction treatment portfolio.
  • The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

Retrieved on: 
星期三, 十月 12, 2022
Oxycodone, Drug overdose, Pharmacology, CDC, Infection, U.S. Securities and Exchange Commission, Therapy, SEC, OUD, Methadone, Respiration, Hypoventilation, Annual report, Part, Patient, Part Two, Depression, Research, Opioid use disorder, Security (finance), Mental health, Nasdaq, Drug, Private Securities Litigation Reform Act, NEW, Columbia University, Addiction, Respiratory rate, MOR, Buprenorphine, CEO, Pain, Food, GLOBE, Anxiety, Public expenditure, PK, Intellectual property, Forward-looking statement, Naltrexone, Death, Failure, FDA, COVID-19, List of life sciences, Vaccine, Medicinal plants, Pharmaceutical industry, Kurash

NEW YORK and BERLIN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) announced today positive initial results for their Phase 1 clinical trial of KUR-101. KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD).

Key Points: 
  • KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD).
  • Approximately 3 million people in the U.S. are diagnosed with OUD, and relapse occurs in up to 75% of patients.
  • NEW YORK and BERLIN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (atai) announced today positive initial results for their Phase 1 clinical trial of KUR-101.
  • KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD).

Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder

Retrieved on: 
星期四, 十月 6, 2022
National Institute, Drug overdose, Half-life, Therapy, Alcoholism, JAMA Psychiatry, Media, NASDAQ, Patient, Research, Risk, Endorphins, Drinking, National Institute on Alcohol Abuse and Alcoholism, Absorption, Centers for Disease Control and Prevention, WHO, Treatment, Trial of the century, Addiction, Naltrexone, PMID, Safety, Placebo, World Health Organization, GLOBE, Plasma, Ageing, NCHS, Death, Terminology, AUD, The Journal of Clinical Pharmacology, Epidemiology, Rural area, Pharmaceutical industry

Opiant launched its Phase 2 clinical study of OPNT002 for the treatment of alcohol use disorder in January 2022.

Key Points: 
  • Opiant launched its Phase 2 clinical study of OPNT002 for the treatment of alcohol use disorder in January 2022.
  • Clinical and preclinical studies have shown that alcohol releases endorphins, which are the brains endogenous opioids.
  • Alcohol use disorder is a chronic relapsing brain disease characterized by compulsive use of alcohol and the inability to control intake.
  • Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.

2B3D Shares Addiction Treatment Deliverables from BioCorRx for Phase I of Mental Health Metaverse Platform Beta

Retrieved on: 
星期四, 九月 29, 2022
Fentanyl, Nutritionist, FDA, NFT, Company, Morphine, CBT, Catalog, Mitsubishi 380, Curriculum, Virtual reality, CEO, Cognitive behavioral therapy, Veteran, Solution, Friends, CA, Family, Non-fungible token, Drug development, Behavior, Addiction, Foundation for the National Institutes of Health, Naltrexone, GLOBE, PTSD, National Institute, Pharmaceutical industry, VR

Los Angeles, CA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – 2B3D, a military veteran-operated mental health technology solutions firm specializing in VR, Gaming, NFTs, developing metaverse solutions for PTSD and addiction treatment, today announced the scope of deliverables from its addiction treatment partner, BioCorRx.

Key Points: 
  • 2B3Ds end-to-end prototype for live, free PTSD treatment for military veterans allows platform users to self-identify addiction issues upon first arrival in the VR Medical Environment (VRME).
  • BioCorRxs course modules are a popular and well-tested component of the firms Beat Addiction Recovery Program, a non-metaverse treatment therapy that is largely app-driven.
  • In 2B3Ds metaverse, military veterans will be able to reach out to mental health professionals using a customized avatar for more personalized online interactions.
  • BioCorRx Inc. is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders.

Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial

Retrieved on: 
星期一, 九月 12, 2022
Safety, Therapy, ISIN, Sorbitol, FDA, ClinicalTrials.gov, Prevalence, Neurodegeneration, Life, Baclofen, Muscle, Muscle atrophy, Treatment, Patient, Wheelchair, Risk, Phase II, PMP22, III, Schwann cell, Walking, Running, CMT, CET, Charcot–Marie–Tooth disease, Regulatory News Service, Naltrexone, HD, Occupational therapy, Marketing, EMA, Disease, Pharmaceutical industry, Security (finance)

Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial

Key Points: 
  • Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The dose of PXT3003 tested in the PREMIER trial corresponds to the HD tested in the prior Phase III clinical study, the PLEO-CMT trial, and the ongoing open-label extension Phase III study, the PLEOCMT-FU trial.
  • The dose of PXT3003 tested in the PREMIER trial corresponds to the high dose (HD) tested in the prior Phase III trial (PLEO-CMT).
  • An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing.

BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
星期二, 九月 6, 2022
CEO, CBT, Solution, Addiction, CFO, Cognitive behavioral therapy, GLOBE, Conference, Company, FDA, Naltrexone, Lotte New York Palace Hotel, Substance abuse, Drug development, OTCQB, Nutritionist, Pharmaceutical industry

The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.

Key Points: 
  • The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.
  • The Companys presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 12, 2022, at 7:00 AM Eastern Time.
  • Management will also be participating in one-on-one meetings with qualified members of the investment community throughout the conference.
  • BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders.

BioCorRx Provides Business Update for the Second Quarter of 2022

Retrieved on: 
星期二, 八月 16, 2022
FDA, U.S. Securities and Exchange Commission, AUD, NIH, Curriculum, GLOBE, Naltrexone, CFO, CEO, Addiction, CA, CBT, Orange County, National Institute, IND, National, Security (finance), Substance abuse, Clinical trial, Nutritionist, MAT, Cognitive behavioral therapy, RFA, Company, OUD, Program, National Institute on Drug Abuse, NIDA, Safety, Drug development, Post-traumatic stress disorder, Research, OTCQB, Veteran, Solution, NCT, PTSD, Volunteering, Annual report, Opioid use disorder, Pharmacokinetics, Investigational New Drug, Pharmaceutical industry, Drug overdose

ANAHEIM, CA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire BioCorRx Inc. (OTCQB: BICX) (the Company), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and reported on recent corporate developments.

Key Points: 
  • ANAHEIM, CA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire BioCorRx Inc. (OTCQB: BICX) (the Company), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and reported on recent corporate developments.
  • We are pleased to report that this month we have enrolled and dosed several more subjects.
  • We believe this program will offer veterans suffering with substance abuse and other related disorders an enhanced treatment solution.
  • A copy of the Companys annual report on Form 10-Q for the second quarter ended June 30, 2022 has been filed with the Securities and Exchange Commission and posted on the Companys website at https://ir.biocorrx.com/ .

U.S. Substance Abuse Treatment Market Research Report 2022: Surging Rate of Drug Addiction And the Growing Prevalence of Alcohol and Smoking Among U.S. Teenagers Driving Growth - ResearchAndMarkets.com

Retrieved on: 
星期二, 八月 2, 2022
General Health, Pharmaceutical, Health, Other Health, Market share analysis, Acquisition, R, Investment, State, Value, Decision-making, Smoking, Cognitive behavioral treatment of eating disorders, Use, Cocaine, North American gambling treatment centers, Passages Malibu, Pharmacy, Bupropion, Research, Hospital, Strategic management, Group, Methadone, Customer support, USD, Naltrexone, CAGR, Certification, Substance Abuse, Patient, Awareness, Nicotine, Market share, Discrimination against drug addicts, Prevalence, Drug, Growth, Rate, Business Growth Fund, California Substance Abuse Treatment Facility and State Prison, Corcoran, Retail, Varenicline, Buprenorphine, Acamprosate, Disulfiram

This research report categorizes the Substance Abuse Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Substance Abuse Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Substance Abuse Type, the market was studied across Alcohol Addiction, Cocaine, Marijuana, and Nicotine Addiction.
  • Based on Treatment Option, the market was studied across Group Counseling, In-patient Treatment, Individualized Drug Counseling, Long-Term Residential Treatment, Outpatient Treatment Programs, and Short-Term Residential Treatment.
  • Based on State, the market was studied across California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio, Pennsylvania, Tennessee, Texas, and Wisconsin.
  • Surging Rate of Drug Addiction And the Growing Prevalence of Alcohol and Smoking Among U.S. Teenagers
    Rising Patient Awareness through Significant Drug Awareness Campaigns and Prevention Programs in the U.S.